Regulation of Combination Products (cGMP Requirements)
FDA 21 CFR Part 4 establishes current good manufacturing practice (cGMP) requirements for combination products — products comprising two or more regulated constituent parts (drug, device, and/or biological product). Subpart A allows manufacturers of single-entity and co-packaged combination products to operate under either the drug cGMPs (21 CFR 210/211) or the device Quality System Regulation (21 CFR 820) as a base, then demonstrate compliance with specified provisions called out from the other — the streamlined approach. Subpart B addresses postmarketing safety reporting.
What this does not cover
stated in the document's own scope- Does not apply to products with a single constituent part
- Does not replace 210/211 or 820 — it specifies how they combine
- Does not decide product jurisdiction/classification (that is the Office of Combination Products / RFD process)
- Subpart A does not itself cover postmarketing safety reporting — that is Subpart B
Always verify against the current published text before relying on it for a submission or inspection.
Overview
FDA 21 CFR Part 4 establishes current good manufacturing practice (cGMP) requirements for combination products — products comprising two or more regulated constituent parts (drug, device, and/or biological product). Subpart A (Part 4.1-4.4) allows manufacturers of single-entity and co-packaged combination products to operate under either the drug cGMPs (21 CFR 210/211) or the device Quality System Regulation (21 CFR 820) as a base system, and then demonstrate compliance with specified provisions called out from the other regulation — the streamlined approach. Subpart B addresses postmarketing safety reporting requirements for combination products.
Legal basis & how it acquires force
Part 4 is a codified FDA regulation issued under the authority of the FD&C Act and the Public Health Service Act, established by final rule in the Federal Register. It is legally binding on combination-product manufacturers. It interprets and coordinates the predicate cGMP rules — the drug cGMPs (21 CFR 210/211) and the device quality system requirements (21 CFR 820) — for products that contain more than one constituent part.
Document structure
| Part | Covers |
|---|---|
| Subpart A — 4.1 Definitions | Combination product types: single-entity, co-packaged, cross-labeled |
| Subpart A — 4.2 Applicable regulations | Which cGMP regulations apply to each constituent part |
| Subpart A — 4.3/4.4 Compliance approaches | Demonstrating compliance and the streamlined called-out provisions |
| Subpart B — Postmarketing safety reporting | Reporting requirements for combination products |
Key requirements
- Determine the combination product type (single-entity, co-packaged, or cross-labeled)
- Choose a compliant base cGMP operating system (drug 210/211 or device 820) for the streamlined approach
- Satisfy the specified called-out provisions from the other constituent part regulation
- Under a drug base, meet device design controls (820.30), CAPA (820.100), and related called-out clauses
- Under a device base, meet specified drug cGMP provisions (e.g. 211 stability, expiration dating)
- Comply with Subpart B postmarketing safety reporting requirements for combination products
- Document the applied compliance approach and constituent-part responsibilities
Implementation tips
- Decide the base operating system early — retrofitting design controls onto a 211-only quality system is costly
- Note the QSR-to-QMSR transition (21 CFR 820 aligning to ISO 13485) affects the device-side called-out clauses
- Map every called-out provision to a procedure so a called-out clause is not silently unaddressed
- Coordinate with the lead Center/OCP jurisdiction determination for the constituent parts
International alignment
Part 4 coordinates the FDA drug cGMPs (21 CFR 210/211) and the device quality system requirements (21 CFR 820); the latter is being aligned with ISO 13485 under the Quality Management System Regulation (QMSR) transition, which affects the device-side called-out provisions referenced by Part 4.
21 CFR Part 4: frequently asked questions
Quick answers to common questions about 21 CFR Part 4.
What is the streamlined approach under Part 4?
Operate under one base cGMP system (drug 210/211 or device 820) and comply with specified called-out provisions from the other, rather than fully duplicating both.
Which device provisions are called out under a drug base?
Specified 21 CFR 820 provisions including design controls (820.30), CAPA (820.100), purchasing controls, and installation/servicing where applicable.
What does Subpart B cover?
Postmarketing safety reporting requirements specific to combination products.